New Novartis Analyses for Investigational Inclisiran Demonstrate Consistently Effective and Sustained LDL-C Reduction at Month 17, Regardless of Age and Gender
EAST HANOVER, N.J., Nov. 13, 2020 /PRNewswire/ — Novartis today announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and
Read more